Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Small Pharma Inc. plans Phase 2b trial of DMT for depression

By Brian Buntz | November 18, 2021

Small PharmaSmall Pharma Inc. (TSXV:DMT) is prepping a Phase 2b clinical study to test the use of its lead candidate, SPL026, an N, N-dimethyltryptamine (DMT) in treating major depressive disorder (MDD).

DMT is present in Ayahuasca, a South American psychedelic brew.

The company has announced that it has had positive discussions with FDA regarding the planned trial.

“Importantly, the FDA’s feedback facilitates a path forward to prepare for the inclusion of U.S. sites in our Phase 2b clinical trial, which we anticipate will also be conducted across sites in Europe and the UK,” said Dr. Carol Routledge, chief medical and scientific officer of Small Pharma. “We believe that Small Pharma is conducting the first clinical trials of a DMT-assisted therapy for patients with MDD, with the potential to provide a much-needed alternative treatment for patients suffering from this debilitating condition.”

The company Small Pharma chose its name as a reaction to the phrase “Big Pharma.” Founded in 2015, the company has a pipeline focused on DMT and a ketamine metabolite.

Scientific interest in DMT, currently a Schedule I controlled substance in the U.S., has grown recently as drug developers have explored the potential of psychedelics to treat depression, post-traumatic stress disorder and other conditions.

Neuropharmacology published an article in July found DMT could be a potential adjuvant pharmacological therapy to manage acute cerebral ischemia.

In October, the Journal of Psychopharmacology published an article concluding that the drug has “potential beneficial long-term effects on mental health and well-being.” The paper also reasoned that, while further “exploration is warranted,” so are “precautions” to limit the potential of abuse and negative drug-drug interactions.

In 2019, Psychopharmacology found that DMT can lead to “sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.”

 


Filed Under: Neurological Disease, Psychiatric/psychotropic drugs
Tagged With: Ayahuasca, DMT, FDA, major depressive disorder, MDD, Small Pharma
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Aduhelm
Nine out of ten U.S. neurologists have Aduhelm efficacy doubts
Athira Pharma
​​Athira Pharma to continue open-label Alzheimer’s extension studies
Biogen
Biogen CEO Michel Vounatsos to step aside as Aduhelm sales continue to sputter
Janssen
Why Janssen’s nipocalimab could represent a ‘pipeline in a pathway’

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50